Amsterdam

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD

Retrieved on: 
Tuesday, October 24, 2023
Optimism, Jort, AECC, Dementia, Clinical trial, Poster, Brain, EEG, Synaptic, Cognition, Therapy, Amsterdam, Quantitative electroencephalography, SEQUEL, Communication, Medical device, Medical imaging

SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.

Key Points: 
  • SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator.
  • The poster describing changes in brain wave patterns in adults with mild-to-moderate Alzheimer’s disease following 28-days of treatment with CT1812 or placebo will be on display through the conclusion of CTAD.
  • In the SEQUEL study , CT1812-treated participants exhibited a statistically significant change in relative theta in the central region of the brain and consistent trends of improvement across all prespecified EEG parameters.
  • “CT1812 treatment showed improvement of EEG parameters that are consistent in magnitude and effect size with previously reported trials,” explained Dr. de Haan.

Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders

Retrieved on: 
Tuesday, October 17, 2023
Identification, UMC, Cognition, Deficit spending, Research, Caregiver, Toxicity, Data, Cell therapy, Safety, Cogstate Brief Battery, Memory, Amsterdam, EEG, DSMB, Data monitoring committee, Fraunhofer Society, MCI, Immunology, QPCT, CBB, Pathology, AD, NTB, Patient, Euronext Amsterdam, Medical imaging, Pharmaceutical industry, Medical device, Amyloid beta

AD is a disorder of cognition, not just memory and MCI and early AD are characterized by a variety of cognitive deficits.

Key Points: 
  • AD is a disorder of cognition, not just memory and MCI and early AD are characterized by a variety of cognitive deficits.
  • It has the advantage of investigating a broad range of cognitive domains acknowledged to be clinically meaningful measures of function.
  • reliability and validity, support its use as an outcome measure in treatment evaluation studies and for use in clinical practice.
  • Based on the results in the SAPHIR study in early AD patients, theta power has been selected as a key secondary endpoint in the VIVIAD study.

Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease

Retrieved on: 
Thursday, July 27, 2023
CD, Therapy, Inflammatory Bowel Diseases, IBD, Disease, Amsterdam, Inflammation, Fibrosis, Vant, Patient, CDAI, Safety, Pharmaceutical industry, UC, Roivant Sciences

The TAHOE study ( NCT05910528 ) is a global, randomized, double-blind study evaluating two doses of RVT-3101 given once-monthly in patients with moderate to severely active Crohn’s disease.

Key Points: 
  • The TAHOE study ( NCT05910528 ) is a global, randomized, double-blind study evaluating two doses of RVT-3101 given once-monthly in patients with moderate to severely active Crohn’s disease.
  • The primary and key secondary endpoints are the proportion of participants achieving clinical remission by Crohn's Disease Activity Index (CDAI) and the proportion of participants achieving endoscopic response at week 14.
  • This was the first-ever long-duration data reported for an anti-TL1A antibody.
  • Across all doses and patient groups, RVT-3101 was well tolerated and showed a favorable safety profile.

Destination Tomorrow Announces Annual Bronx Pride Week from June 13 to June 17

Retrieved on: 
Monday, June 12, 2023
Park, Black Trans Femmes in the Arts, Grand Concourse, Highbridge, Partnership, Food, Housing, The arts, Transgender, Hostos Center for the Arts & Culture, TD, Amsterdam, Clothing, Work, Black box, Aja, Toronto-Dominion Bank, RuPaul, Gender, ...Continued, HBO Max, FX, Council, Queer, South Bronx, San Francisco Gay Men's Chorus, Westchester, Health, House, Nightclub, Tourism, Pride, The Bronx, Chorus

BRONX, N.Y., June 12, 2023 /PRNewswire/ -- The LGBTQ+ grassroots organization Destination Tomorrow will host its annual Bronx Pride Week in New York from June 13 to June 17. This year's theme, "Investing in Us," celebrates LGBTQ+ individuals and sheds light on the programs, resources and allyship the community needs.

Key Points: 
  • BRONX, N.Y., June 12, 2023 /PRNewswire/ -- The LGBTQ+ grassroots organization Destination Tomorrow will host its annual Bronx Pride Week in New York from June 13 to June 17.
  • Bronx Pride Week arrives amid a political landscape violating the rights and freedoms of the LGBTQ+ community.
  • The center hopes to see everyone in the Bronx to celebrate Pride and show their support for these individuals.
  • The annual Bronx Pride Festival, hosted by Aja from RuPaul's Drag Race and Jack Gorgeous Gucci from FX's Pose and HBO Max's Legendary, will conclude the week of celebration.

Swifty Global Releases Details of Its Annual Shareholder Meeting

Retrieved on: 
Thursday, March 16, 2023
Cape, Amsterdam, Kinsale, EBITDA, Fintech, OTC, News, Swifty

Swifty Global displayed impressive Q4 results, recording close to $24.4 million in revenue and an EBITDA which left the industry in awe.

Key Points: 
  • Swifty Global displayed impressive Q4 results, recording close to $24.4 million in revenue and an EBITDA which left the industry in awe.
  • Swifty Global has since been fully audited and has its sights on filing its S-1 by the end of Q1 2023.
  • At the same shareholder meeting, which took place on the 27th of January 2023, forecasts for 2023 were conferred, with expectations of reaching $100 million in company revenue.
  • For regular updates and information on the company’s latest news, you are invited you to follow Swifty Global on Twitter, LinkedIn and the below specified communication channels.

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

Retrieved on: 
Tuesday, September 27, 2022
Theta, Institute, National, Therapy, Central nervous system, Retina, SEQUEL, U.S. Securities and Exchange Commission, Safety, Degenerative disease, Securities & Exchange Commission of Pakistan, Lewy body, COVID-19, Brain, Amsterdam, Intellectual property, National Institute on Aging, MMSE, Cognition, DLB, Patient, NIA, Risk, CEO, Jort, Vance DeGeneres, Nasdaq, Private Securities Litigation Reform Act, Dementia, Research, EEG, GLOBE, Quantitative electroencephalography, NIH, National Institute, Pharmaceutical industry

The aim of the SEQUEL trial is to investigate whether treatment with CT1812 results in a normalization of the EEG patterns, as measured by quantitative electroencephalogram (qEEG).

Key Points: 
  • The aim of the SEQUEL trial is to investigate whether treatment with CT1812 results in a normalization of the EEG patterns, as measured by quantitative electroencephalogram (qEEG).
  • We also want to extend our gratitude to the patients who enrolled in SEQUEL and the team at Amsterdam UMC who remained engaged through the pandemic.
  • After a 14-day wash-out period, participants cross over into the other treatment arm for an additional 28 days (period 2).
  • The NIA awarded Cognition a $3.2 million grant (R01AG058710) in 2020 to support the study and has now subsequently awarded $2.14 million in 2022.

Adagio Medical Announces Publication of Cryocure-2 Data Reporting 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Discusses Current Status of iCLAS™ Cryoablation System

Retrieved on: 
Thursday, July 28, 2022
Atrial flutter, Amsterdam, University, Freedom, Population, Doctor of Philosophy, Arrhythmia, VT, Temperature, Ventricular tachycardia, NCT, CEO, Heart Rhythm Society, Catheter ablation, Safety, Associate Director of National Intelligence and Chief Information Officer, Journal, Atrial fibrillation, EP, Technology, University of Bordeaux, FDA, ICLA, MD, Patient, RF, JACC, Lists of Palestinian rocket attacks on Israel, AF, Manuscript, Medical device, Adagio

The one-year freedom from AF after a single procedure was 82%, with 1.5% procedural complications rate when using ULTC technology.

Key Points: 
  • The one-year freedom from AF after a single procedure was 82%, with 1.5% procedural complications rate when using ULTC technology.
  • "Today's publication reaffirms the interest of the EP community in ULTC technology for the treatment of AF and other cardiac arrhythmias.
  • The Cryocure-PMCF (NCT # 05416086) open-label post-market clinical follow-up evaluation of iCLAS system isenrolling both paroxysmal and persistent AF patients at several European centers.
  • The safety and effectiveness of the iCLAS system for the treatment of persistent AF is a subject of FDA IDE trial in the US (NCT # 04061603).

Adagio Medical Announces Publication of Cryocure-2 Data Reporting 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Discusses Current Status of iCLAS™ Cryoablation System

Retrieved on: 
Thursday, July 28, 2022
Atrial flutter, Amsterdam, University, Freedom, Population, Doctor of Philosophy, Arrhythmia, VT, Temperature, Ventricular tachycardia, NCT, CEO, Heart Rhythm Society, Catheter ablation, Safety, Associate Director of National Intelligence and Chief Information Officer, Journal, Atrial fibrillation, EP, Technology, University of Bordeaux, FDA, ICLA, MD, Patient, RF, JACC, Lists of Palestinian rocket attacks on Israel, AF, Manuscript, Medical device, Adagio

The one-year freedom from AF after a single procedure was 82%, with 1.5% procedural complications rate when using ULTC technology.

Key Points: 
  • The one-year freedom from AF after a single procedure was 82%, with 1.5% procedural complications rate when using ULTC technology.
  • "Today's publication reaffirms the interest of the EP community in ULTC technology for the treatment of AF and other cardiac arrhythmias.
  • The Cryocure-PMCF (NCT # 05416086) open-label post-market clinical follow-up evaluation of iCLAS system isenrolling both paroxysmal and persistent AF patients at several European centers.
  • The safety and effectiveness of the iCLAS system for the treatment of persistent AF is a subject of FDA IDE trial in the US (NCT # 04061603).

Steadman Philippon Research Institute and U.S. Olympic & Paralympic Committee to conduct sixth annual Injury Prevention Symposium April 27-28

Retrieved on: 
Tuesday, April 26, 2022
USOPC, Chronic traumatic encephalopathy, Concussion, Athlete, IOC, CTE, Research, MDT, Leadership, GLOBE, Department, Doctor of Philosophy, Program, Head Injuries, 2020 U.S. Olympic Team Trials (wrestling), Amsterdam, Mental health, United States Olympic & Paralympic Committee, Movement, Female, SPRI, Occupational safety and health, Amsterdam Institute of Finance, College of Arts and Sciences, Sports medicine, Injury, Kropyvnytskyi Region Universal Research Library, Management, Dietary supplement, Paralympic Games, Sport, Health, Safety

VAIL, Colo., April 26, 2022 (GLOBE NEWSWIRE) -- Steadman Philippon Research Institute (SPRI) and the United States Olympic & Paralympic Committee (USOPC) announced that the sixth annual Injury Prevention Symposium will be presented as a live webinar for the third consecutive year.

Key Points: 
  • VAIL, Colo., April 26, 2022 (GLOBE NEWSWIRE) -- Steadman Philippon Research Institute (SPRI) and the United States Olympic & Paralympic Committee (USOPC) announced that the sixth annual Injury Prevention Symposium will be presented as a live webinar for the third consecutive year.
  • That format opened the symposium into something even bigger and better, as we experienced tremendous growth and interest in the event.
  • Dr. Verhagen will kick off the Injury Prevention Symposium with his keynote address on April 27 at 9 a.m. MDT.
  • For further information on the virtual Injury Prevention Symposium, contact Lynda Sampson, vice president of external affairs at SPRI ( [email protected] ).

AtriAN Medical's Clinical Data Highlighted at the 2022 AF Symposium

Retrieved on: 
Monday, January 17, 2022
Patient, PFA, Technology, Amsterdam, Catheter, Safety, Atrial fibrillation, Recurrence, University of Ottawa Heart Institute, Heart, Mount Sinai Hospital, Nervous system, Engineering, CABG, Medical imaging, Health insurance

GALWAY, Ireland, Jan. 17, 2022 /PRNewswire/ -- Irish medical device company AtriAN Medical today announced that clinical data from it's first-in-human study was presented at this years renowned Annual AF Symposium in New York City.

Key Points: 
  • GALWAY, Ireland, Jan. 17, 2022 /PRNewswire/ -- Irish medical device company AtriAN Medical today announced that clinical data from it's first-in-human study was presented at this years renowned Annual AF Symposium in New York City.
  • AtriAN has to-date enrolled nineteen patients in the company's Neural AF multi-center study, using a unique cardiac autonomic ablation technology for the treatment of atrial fibrillation.
  • An update on the clinical data was presented by Prof Vivek Reddy MD of Mount Sinai Hospital (NY), at the session on Late Breaking Clinical Trials and First Report Investigations, on January 14th, 2022.
  • For more information about AtriAN Medical, please visit: www.atrianmedical.com
    About AtriAN Medical: AtriAN Medical is anIrish medical devicecompany based in Galway.